1.545
Pacific Biosciences Of California Inc stock is traded at $1.545, with a volume of 1.29M.
It is down -0.32% in the last 24 hours and down -9.33% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.56
Open:
$1.545
24h Volume:
1.29M
Relative Volume:
0.18
Market Cap:
$466.59M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.03
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-12.64%
1M Performance:
-9.33%
6M Performance:
+22.44%
1Y Performance:
+16.04%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PACB
Pacific Biosciences Of California Inc
|
1.545 | 471.12M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
110.93 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
373.31 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
92.92 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.02 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.12 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com India
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
PACB,TAL Volatility & Greeks - Finviz
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Finviz
Intuitive Surgical Expands Direct Operational Presence in Europe - Finviz
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB) - Finviz
Equity awards to Pacific Biosciences (PACB) officer disclosed - Stock Titan
PACB (PACB) grants James R. Gibson II 667,696 options and 333,848 RSUs - Stock Titan
Pacific Biosciences (PACB) officer receives large option and RSU awards - Stock Titan
Large equity grants to PacBio (PACB) executive highlight retention focus - Stock Titan
Christian Henry sells 472,667 PACB shares (PACB) on Form 144 - Stock Titan
PacBio and DNAstack Join Forces to Launch Worldwide HiFi Genome Network Hub - Bitget
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - Yahoo Finance
Pacific Biosciences of California enables automatic epigenetic data in HiFi sequencing runs - Traders Union
Pacific Biosciences of California backs San Diego event to strengthen rare disease awareness - Traders Union
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
PACB,TAL Revenue Breakdown - Finviz
Pacific Biosciences of California joins IRDiRC to advance rare disease research - Traders Union
Vestmark Advisory Solutions Inc. Sells 692,663 Shares of Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pacific Biosciences of California (PACB) Stock Analysis: A 53% Upside Awaits in the Genomic Sequencing Arena - DirectorsTalk Interviews
Pacific Biosciences Of California Files For Mixed Shelf Size - TradingView
[10-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files Annual Report | PACB SEC FilingForm 10-K - Stock Titan
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Joins Forces with DNAstack for Global Genomic Data Collaboration - GuruFocus
Volume Recap: Is Pacific Biosciences of California Inc stock a buy or sell2025 Winners & Losers & Free Reliable Trade Execution Plans - baoquankhu1.vn
PacBio and DNAstack launch first global federated HiFi whole genome dataset to accelerate rare disease research - marketscreener.com
Global genome network to speed answers for rare disease patients - Stock Titan
Pacific Biosciences of California examines technology impact on DNA sequencing insights - Traders Union
Pacific Biosciences COO Sells Shares - Intellectia AI
Why The PacBio (PACB) Narrative Is Shifting Around Fair Value And Long Read Sequencing - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by Zacks Research - MarketBeat
Will Pacific Biosciences of California Inc. outperform tech stocksMarket Movers & Weekly Stock Performance Updates - mfd.ru
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 331,793 Shares - MarketBeat
Van Oene Mark sells PACB shares worth $294,318 By Investing.com - Investing.com Canada
Farmer of Pacific Biosciences sells $79,855 in stock By Investing.com - Investing.com South Africa
Van Oene Mark sells PACB shares worth $294,318 - Investing.com
Farmer of Pacific Biosciences sells $79,855 in stock - Investing.com
5 Must-Read Analyst Questions From PacBio's Q4 Earnings Call - Finviz
PacBio (PACB) Q4 2025 Earnings Call Transcript - AOL.com
PacBio (PACB): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
PacBio stock up on HiFi sequencing adoption for major SUDC research - MSN
PacBio leaders set for TD Cowen health conference webcast - Stock Titan
Pacific Biosciences of California : PACB Q4 2025 Earning Prepared Remarks - marketscreener.com
Exit Recap: Should I invest in Clene Inc before earningsEarnings Risk Summary & Stepwise Swing Trade Plans - baoquankhu1.vn
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):